EnzyQuest signs commercial agreement with FO.R.T.H.
EnzyQuest signs commercial agreement with FO.R.T.H. (Foundation for Research and Technology – Hellas) for exclusive commercial exploitation of more than 70 molecular biology products developed by the Institute of Molecular Biology and Biotechnology (IMBB-FORTH).
The Foundation for Research and Technology – Hellas (FORTH) was founded in 1983. It is one of the largest research centers in Greece with well-organized facilities, highly qualified personnel and a reputation as a top-level research institution worldwide.
In 2019, FO.R.T.H. was ranked first (1st) among all Research Centers in Greece , 56th in Europe and 130th Internationally, out of 8,138 Research Centers worldwide, according to the Global “Ranking Web of Research Centers”.
EnzyQuest receives a VC fund from Uni.Fund
EnzyQuest, receives a VC fund (400K €) from Uni.Fund, an EquiFund partner (EquiFund is an initiative created by the Hellenic Republic in cooperation with the European Investment Fund).
According to Uni.Fund, EnzyQuest is the first company that is active in the field of enzyme biotechnology in Southeast Europe. Having already 70 products in its portfolio, as well as a number of new ones under development, EnzyQuest enters dynamically on the world map, with a strong and innovative element of the identification and discovery of enzymes with new properties and pioneering applications by Extremophilic organisms, i.e. microorganisms that have developed enzymes that operate in extreme conditions (saltness, temperature, etc.).